IA en un minutoNewsBusiness and products
Anthropic acquires Mithril Medicine, a biotech researching rare muscular dystrophies
IA en un minuto newsroom · Editor: Jon Elgezabal
In 30 seconds
Anthropic has taken over Mithril Medicine, a small company chasing drugs for two rare muscular dystrophies. Claude served as the operational engine with 11 external labs, and the team says that, within 18 months, it already had encouraging results in mice. Cody Tranbarger, its founder, continues the research inside Anthropic, although everything is still preclinical and human trials would come, at the earliest, in late 2028.
Anthropic has acquired Mithril Medicine, a one-person company that was developing treatments for two rare forms of muscular dystrophy. The company announced it on October 27 in a post on its progress in drug development.
Its founder, Cody Tranbarger, relied on Claude, Anthropic's AI assistant, to handle contracts, logistics and experiments across 11 outside labs, and passed it much of the rest of the operation. According to Anthropic, that let him take a possible treatment for one of the two diseases from a concept to encouraging mouse-study results in under 18 months. Tranbarger now continues that research inside Anthropic and plans to launch several new programs.
If the drug candidates hold up, Anthropic expects to have one ready to start human trials in late 2028 at the earliest. The company itself stresses that all this work is at an early stage and mostly preclinical, meaning not yet tested in people.
According to Infobae, Mithril is based in Cambridge, Massachusetts, and the deal closed in July. The outlet adds that its main program targets congenital muscular dystrophy linked to the LAMA2 gene and the second one targets alpha-dystroglycanopathy. It also reports that the technical report, still without peer review, admits limitations: the treatment was assigned by litter, without randomization. The plan is to choose drug candidates in 2027 and start human trials with the LAMA2 one in late 2028 and with the other in 2029. Infobae also says the team went over six Claude failures and that at least three reached external labs.
Mithril joins the collaborations Anthropic has kept up for months with six organizations in the sector: Generate Biomedicines, The Column Group, Enveda, Divergence Labs, Bristol Myers Squibb and BigHat Biosciences. Anthropic says it had already started drug discovery programs of its own and wants to bring Claude into every stage of development, from choosing the target to planning clinical trials.
Why it matters · analysis and opinion
The deal shows an AI model company moving into the costliest and slowest part of medicine: it no longer just sells its assistant, it runs programs of its own. Mithril works as a showcase, because a single person handed Claude much of the coordination with outside providers. What matters most, however, remains to be shown. The results come from mice, the technical report has not yet been peer reviewed and, according to Infobae, admits design limitations. Moreover, the Claude errors that reached external labs are a reminder that human oversight is still needed. For a company in any sector, the practical lesson is that handing logistics and paperwork to an assistant can save time, as long as someone checks each shipment before it goes out.
Official source: Anthropic · Written with the help of AI: how we make the news
